NTRK3 Amplification

CI-VAR-00000230Explore in graph →CIViC 1281

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm2
NTRK1 Amplification OR NTRK3 Amplification OR NTRK2 Amplification	Entrectinib	Predictive	B	Does Not Support Sensitivity Response	1	accepted	EID2958 Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. … (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC	civic
NTRK3 Amplification	Entrectinib	Predictive	B	Does Not Support Sensitivity Response	1	accepted	EID2959 Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. … (full text at CIViC) PMID 28183697 · Drilon et al., 2017 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.